New AI tool revolutionizes insulin resistance detection and cancer risk assessment

A new AI tool called AI-IR is changing how doctors assess insulin resistance. Developed by researchers at the University Hospital Tokyo, it uses routine health data to give more accurate results than traditional methods like BMI. The discovery could improve cancer prevention and early diagnosis by identifying high-risk individuals more effectively.

The AI-IR model works by analysing nine standard clinical parameters from regular health check-ups. Unlike BMI, which can produce misleading results, this tool provides a clearer picture of insulin resistance. Tests showed it was far more precise in spotting at-risk patients.

Similar approaches have been explored elsewhere. The Mayo Clinic in the USA developed a comparable system in 2023, followed by the University of Oxford in 2024 and Charité Berlin in 2025. However, the Tokyo study stands out for its scale and focus on cancer risk.

Yuta Hiraike, the study's lead author, explained that AI-IR is the first tool to confirm insulin resistance as a cancer risk factor across large populations. Researchers are now examining how genetic differences affect individual cancer risks linked to insulin resistance. The findings could lead to better-targeted screening programmes.

The AI-IR tool offers a practical way to detect insulin resistance early. Its accuracy and ease of use make it suitable for widespread health screening. With further research, it may help reduce cancer cases by enabling earlier interventions and personalised prevention strategies.